evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Tixagevimab/cilgavimab vs placebo

Infection with SARS‐CoV‐2 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Tixagevimab/cilgavimab probably leads to lower infection with SARS‐CoV‐2 within 6 months compared with placebo (moderate certainty).

1 finding from 1 review

Casirivimab/imdevimab vs placebo

Development of clinical COVID‐19 symptoms within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Casirivimab/imdevimab may leads to lower development of clinical COVID‐19 symptoms within 6 months compared with placebo (low certainty).

1 finding from 1 review

Casirivimab/imdevimab vs placebo

Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

The review found no eligible studies for this question.

2 findings from 1 review

Casirivimab/imdevimab vs placebo

Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

The review found no eligible studies for this question.

2 findings from 1 review

Casirivimab/imdevimab vs placebo

Grades 3 and 4 adverse events · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

It is very uncertain whether casirivimab/imdevimab changes adverse events: grade 3 to 4 within 6 months compared with placebo (very low certainty).

2 findings from 1 review